Letters In Drug Design And Discovery impact factor, indexing, ranking (2024)


letters

Aim and Scope

The Letters In Drug Design And Discovery is a research journal that publishes research related to Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics. This journal is published by the Bentham Science Publishers B.V.. The ISSN of this journal is 15701808. Based on the Scopus data, the SCImago Journal Rank (SJR) of letters in drug design and discovery is 0.192.

Also, please check the following important details about letters in drug design and discovery: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.

According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.

Letters In Drug Design And Discovery Ranking

Journal Rank: 19611
SJR (SCImago Journal Rank): 0.192
Quartile: Q3
H-Index: 36

The SJR (SCImago Journal Rank) measures citations weighted by prestige. It is useful for comparing journals within the same field, and forms the basis of the subject category ranking. A journal SJR indicator is a numeric value representing the average number of weighted citations received during a selected year per document published in that journal during the previous three years, as indexed by Scopus. Higher SJR indicator values are meant to indicate greater journal prestige. SJR is developed by the Scimago Lab, originated from a research group at University of Granada. Q1 journals are cited more often and by more prestigious journals than those in the other quartiles.

Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.

CiteScore of an academic journal is a measure reflecting the yearly average number of citations to recent articles published in that journal. This journal evaluation metric was launched in December 2016 by Elsevier as an alternative to the generally used JCR impact factors (calculated by Clarivate). CiteScore is based on the citations recorded in the Scopus database rather than in JCR, and those citations are collected for articles published in the preceding four years instead of two or five.

Source Normalized Impact per Paper (SNIP) is calculated annually from Scopus data. It is a sophisticated metric that intrinsically accounts for field-specific differences in citation practices.



Important Metrics

Journal Title: Letters in Drug Design and Discovery
Publisher: Bentham Science Publishers B.V.
ISSN: 15701808
Type: journal
Journal Scope: Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics
Country: United Arab Emirates
H-Index: 36
SJR: 0.192
Quartile: Pharmaceutical Science (Q3); Drug Discovery (Q4); Molecular Medicine (Q4)

letters in drug design and discovery Indexing

The letters in drug design and discovery is indexed in:

An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.

The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).


Letters In Drug Design And Discovery Quartile

The latest Quartile of letters in drug design and discovery is Q3.

Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.


Journal Publication Time

The publication time may vary depending on factors such as the complexity of the research and the current workload of the editorial team. Journals typically request reviewers to submit their reviews within 3-4 weeks. However, some journals lack mechanisms to enforce this deadline, making it difficult to predict the duration of the peer review process.

The review time also depends upon the quality of the research paper.



Call for Papers

Visit to the official website of the journal/ conference to check the details about call for papers.

How to publish in Letters In Drug Design And Discovery?

If your research is related to Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics, then visit the official website of letters in drug design and discovery and send your manuscript.

Tips for publishing in Letters In Drug Design And Discovery:

Acceptance Rate

Acceptance rate is the ratio of the number of articles submitted to the number of articles published. Researchers can check the acceptance rate on the journal website. Alternatively, they can contact the editor of the journal.

Final Summary

  • It is published by Bentham Science Publishers B.V..
  • The journal is indexed in UGC CARE, Scopus.
  • The (SJR) SCImago Journal Rank is 0.192.

Sources: letters in drug design and discovery







SIMILIAR JOURNALS


CHEMICO-BIOLOGICAL INTERACTIONS

ISSN: 0009-2797
Publisher: ELSEVIER IRELAND LTD

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

ISSN: 1742-5255
Publisher: TAYLOR & FRANCIS LTD

DNA AND CELL BIOLOGY

ISSN: 1044-5498
Publisher: MARY ANN LIEBERT, INC

JOURNAL OF MOLECULAR EVOLUTION

ISSN: 0022-2844
Publisher: SPRINGER

MOLECULAR BIOLOGY AND EVOLUTION

ISSN: 0737-4038
Publisher: OXFORD UNIV PRESS

MOLECULAR PHYLOGENETICS AND EVOLUTION

ISSN: 1055-7903
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE

ONCOGENE

ISSN: 0950-9232
Publisher: SPRINGERNATURE

MOLECULAR REPRODUCTION AND DEVELOPMENT

ISSN: 1040-452X
Publisher: WILEY

COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY

ISSN: 1532-0456
Publisher: ELSEVIER SCIENCE INC

ENVIRONMENTAL POLLUTANTS AND BIOAVAILABILITY

ISSN: 2639-5932
Publisher: TAYLOR & FRANCIS LTD

TOP RESEARCH JOURNALS

Credit and Source: Scopus, Clarivate, UGC CARE.